focus -WSS

focus

author：knowledge 2025-10-01 15:30:22 - browse：8

Black and white illustrated portrait of Mark Parrino — Mark Parrino: "I don’t think the dominant interest is just giving lots more take-homes to patients. There’s more to treatment than that." Molly Ferguson for STAT

Nobody has made more of an impact on methadone treatment than Mark Parrino.

For decades, he’s served as the founder and president of the American Association for the Treatment of Opioid Dependence, a nationwide advocacy group representing methadone clinics. Before AATOD, he ran a statewide advocacy group in New York, having made the jump to politics and policy after working as a clinic director and, before that, as an addiction counselor.

Now, a half-century after he began his career in addiction treatment, Parrino is facing what is perhaps a career-defining fight. In the last few years alone, the nation’s tone on opioid treatment programs (OTPs), as they are known, has shifted significantly. While methadone has long been stigmatized, a growing coalition of advocates, lawmakers, and addiction doctors is now pushing to significantly deregulate methadone treatment — and in particular, to offer it outside the context of the specialized clinics that Parrino has long represented.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Female surgeons have lower rates of long

leisure time

WSS

Female surgeons have lower rates of long

ASCO: AstraZeneca says CAR

Humana CEO Bruce Broussard to step down in 2024

A fraught question for the kids of Alzheimer’s: Is it coming for us?

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

European regulators consider appeal over Amylyx ALS drug

focus

focus

leisure time

Psychedelics group wrestles with new pharma identity

Kaiser's Risant Health gobbled up Geisinger. Who is next?

At least 13 dead in Texas as scorching temps continue

A revolution in caring for preterm infants

How one medical school became remarkably diverse

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

State Dept. review finds Biden bears some blame for Afghanistan failures

Ultragenyx gene therapy for rare liver ailment succeeds in late

George Santos makes 1st court appearance after pleading not guilty to 13 counts

European regulators consider appeal over Amylyx ALS drug

explore

What's changing in Medicare's open enrollment this year?

Peter Marks talks Operation Warp Speed for Rare Diseases

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

BMI, flaws aside, is found to be useful estimate of body fat in youth

Researchers CRISPR chickens in bid to protect them from bird flu

With trial win, GSK could get blood cancer drug back on market

hotspot

leisure time

leisure time

knowledge